Recent Transactions

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

14-Jul-23
$674 million
U.S.A., U.K. flags
Target: 

Juice Plus+

flag not available

Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction

20-Jun-23
Pending
$595 million
United Kingdom flag
Target: 

Lookers Plc

Canada flag
Acquiror: 
Alpha Auto Group

Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

16-Feb-23
Pending
$220 million
U.S.A., U.K. flags
Target: 

Flavor Specialty Ingredients division of IFF

United Kingdom flag
Acquiror: 
Exponent Private Equity

Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

08-Aug-22
Undisclosed
United Kingdom flag
Target: 

UK Operations of Lion Pty Limited

Australia flag
Acquiror: 
Odyssey Inns Ltd

Advised Lion Pty Limited, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings Co., Ltd., on the divestment of its UK operations to Odyssey Inns Ltd.

28-Jul-22
Pending
$1.6 billion
Chile Flag
Target: 

Derco Holdings

United Kingdom flag
Acquiror: 
Inchcape Plc

Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

07-Dec-21
Pending
Undisclosed
Target: 

Interamericana Trading Corporation and Simpson Motors

United Kingdom flag
Acquiror: 
Inchcape plc

Advising Inchcape plc, the leading independent global automotive distributor, on the acquisition of Interamericana Trading Corporation (“ITC”), a leading independent automotive distributor in the Caribbean region, and Simpson Motors, the leading automotive retailer in Barbados, from the Simpson Group

12-Jul-21
Pending
$1.7 billion
United Kingdom flag
Target: 

Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)

United States flag
Acquiror: 
KPS Capital Partners

Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America

07-Jun-21
Undisclosed
Target: 

Rights to General, Right Guard and Dry Idea brands

flag not available
Acquiror: 
N/A

Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

29-Dec-20
$110 million
United States flag
Target: 

Biogix, Inc.

United Kingdom flag
Acquiror: 
Alliance Pharma plc

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

23-Nov-20
$120 million
United Kingdom flag
Target: 

Greencore Group plc

flag not available
Acquiror: 
N/A

Advised Greencore Group plc, a leading UK manufacturer of convenience foods based in Ireland, on its £90mm non pre-emptive equity placing

01-Jul-20
$225 million
United Kingdom flag
Target: 

Cello Health plc

United States flag
Acquiror: 
Arsenal Capital Partners

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

11-Jun-20
$760 million
United States flag
Target: 

CSM Bakery Solutions

United States flag
Acquiror: 
Rhône Group

Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend

10-Jun-20
$134 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

06-Apr-20
$352 million
United Kingdom flag
Target: 

WH Smith PLC

flag not available
Acquiror: 
N/A

Advised WH Smith PLC, one of the UK’s leading retailers, on its £166m non pre-emptive equity placing and new £120mm financing facility

09-Mar-20
$10.6 billion
United Kingdom flag
Target: 

Tesco plc’s Thailand and Malaysia businesses

Thailand flag
Acquiror: 
Charoen Pokphand Group

Advised Tesco plc, a leading UK retailer, on the sale of its Thailand and Malaysia businesses to Charoen Pokphand Group, the Thai conglomerate 

02-Mar-20
$NA
United Kingdom flag
Target: 

Global rights (excluding North America) to ThermaCare (United Kingdom)

Italy flag
Acquiror: 
Angelini Pharma

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

28-Feb-20
$NA
United Kingdom flag
Target: 

Rights to Three Skin Care Brands in Mexico

Mexico flag
Acquiror: 
Grisi Hnos

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the Mexico rights to Hinds, Capent and Eclipsol to Mexico-based Grisi Hnos

Pages

show all